Mark For: OVYDSO™ trademark registration is intended to cover the categories of pharmaceutical preparations for the treatment of COVID 19, coronaviruses, and respiratory and infectious diseases; Pharmaceuticals, namely, prodrugs, protein fusion compounds and inhibitors for the treatment of COVID-19, coronaviruses, and respiratory and infectious diseases; Antiviral prodrugs. [all]
Status
2024-07-20 UTC
LIVE APPLICATION Under Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and that this application has been assigned to an examiner.
(Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use
No
Current Use
No
Intent To Use
Yes
Filed ITU
Yes
44D Filed
No
44E Current
No
66A Current
No
Current Basis
No
No Basis
No
Attorney Name
Lindsay J. Hulley
Attorney Docket Number
035359.0053T
Timeline
2022-11-03
Application Filed
2022-11-07
Location: NEW APPLICATION PROCESSING
2022-11-07
Status: Live/Pending
2022-11-07
Transaction Date
2023-10-10
Published
2023-12-05
Location: INTENT TO USE SECTION
2024-05-07
Status: A first request for extension of time to file a Statement of Use has been granted.
LINDSAY J. HULLEY RUTAN & TUCKER, LLP 18575 JAMBOREE ROAD 9TH FLOOR IRVINE, CA 92612
Good, Services, and Codes
IC 005. US 005 006 018 044 046 051 052. G & S: Pharmaceutical preparations for the treatment of COVID 19, coronaviruses, and respiratory and infectious diseases; Pharmaceuticals, namely, prodrugs, protein fusion compounds and inhibitors for the treatment of COVID-19, coronaviruses, and respiratory and infectious diseases; Antiviral prodrugs
International Codes:
5
U.S. Codes:
005,006,018,044,046,051,052
Type Code
Type
GS0051
Pharmaceutical preparations for the treatment of COVID 19, coronaviruses, and respiratory and infectious diseases; Pharmaceuticals, namely, prodrugs, protein fusion compounds and inhibitors for the treatment of COVID-19, coronaviruses, and respiratory and infectious diseases; Antiviral prodrugs
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2023-10-10
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2023-09-20
APPROVED FOR PUB - PRINCIPAL REGISTER
2023-09-01
ASSIGNED TO EXAMINER
2023-08-17
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2022-11-21
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
2022-11-21
NEW APPLICATION ENTERED IN TRAM
2022-11-07
NEW APPLICATION ENTERED
2022-11-07
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.